15. 5. 2025
Krka Reports First Quarter 2025 Business Results
2 min. read
In the first quarter of 2025, the Krka Group generated revenue of €522.1 million, up 7% year on year, yielding net profit of €152.5 million, up 54% year on year. The Supervisory Board of Krka discussed the Q1 2025 business report of the Krka Group and Krka at its regular meeting yesterday.
President of the Management Board and Chief Executive Jože Colarič explained: ‘The Krka Group continues to operate successfully in 2025. In the first quarter of 2025, we generated the highest sales and net profit to date. Sales increased in five of six sales regions, most key markets, and across all product and service groups. We extended our product portfolio with four new prescription pharmaceuticals. Year-on-year, product and service sales increased by 8% and net profit by over 50%. The high increase in net profit ensued from the net financial result impacted by changes in the value of the Russian rouble. We continue to generate robust cash flow from operating activities, which is sufficient for the smooth settlement of our operating liabilities, investments and the realisation of the long-term dividend policy. The Supervisory and Management Boards proposed shareholders be paid a dividend of €8.25 gross per share for 2024, a 10% increase on last year. Shareholders will vote on this proposal at the 31st Annual General Meeting (AGM) on 10 July 2025. We continue investing in our joint venture Krka Pharma Private Limited, established with our partner Laurus Labs Ltd. in Hyderabad, India, in April 2024, where we hold a 51% stake.’
Financial highlights
| € thousand | Index | ||
| Revenue | 522,114 | 486,145 | 107 |
| – Of which revenue from products and services | 521,456 | 484,104 | 108 |
| Gross profit | 304,417 | 279,941 | 109 |
| Earnings before interest, tax, depreciation and amortisation (EBITDA) | 145,862 | 138,468 | 105 |
| Operating profit (EBIT) | 122,690 | 114,188 | 107 |
| Profit before tax (EBT) | 179,514 | 118,644 | 151 |
| Net profit | 152,484 | 98,772 | 154 |
| R&D expenses | 49,519 | 46,864 | 106 |
| Investments | 21,066 | 26,996 | 78 |
Performance ratios
| Gross profit margin | 58.3% | 57.6% |
| EBITDA margin | 27.9% | 28.5% |
| EBIT margin | 23.5% | 23.5% |
| EBT margin | 34.4% | 24.4% |
| Net profit margin (ROS) | 29.2% | 20.3% |
| Return on equity (ROE) | 26.2% | 17.7% |
| Return on assets (ROA) | 20.5% | 14.1% |
| Liabilities/Equity | 0.276 | 0.256 |
| R&D expenses/Revenue | 9.5% | 9.6% |
Sales
Product and service sales by Region
Region Slovenia,6.2
Region South-East Europe,14.4
Region East Europe,33.9
Region Central Europe,23.8
Region West Europe,18.4
Region Overseas Markets,3.3